Since being approved, Wegovy's popularity has soared, to the point where the drug has made its maker, Novo Nordisk -- for ...

Shortly after crossing the FDA’s finish line, Ionis Pharmaceuticals’ RNA-targeted hereditary angioedema (HAE) treatment ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Indianapolis-based Eli Lilly and Co. is acquiring Cambridge, Mass.-based CoLucid Pharmaceuticals for $960 million, the Indianapolis Business Journal reports. Here’s what you should know. 1. Eli Lilly ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Eli Lilly partners with NVIDIA to build the world’s most powerful AI supercomputer in pharma, accelerating drug discovery and manufacturing innovation.

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major ...

The Trump administration announced its newest pharmaceutical agreement under its Most Favored Nation policy Thursday, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at ...

Eli Lilly's (NYSE: LLY) share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House. However, it's a much different story so far in Trump's ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...